Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Siremadlin (NVP-HDM 201) 是一种有效的、可口服的、高度特异性的 p53-MDM2 相互作用抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 638 | 现货 | ||
5 mg | ¥ 1,370 | 现货 | ||
10 mg | ¥ 1,970 | 现货 | ||
25 mg | ¥ 3,670 | 现货 | ||
50 mg | ¥ 5,280 | 现货 | ||
100 mg | ¥ 7,450 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,670 | 现货 |
产品描述 | Siremadlin (NVP-HDM 201) is a potent, orally bioavailable and highly specific p53-MDM2 interaction inhibitor. |
体外活性 | Siremadlin inhibits both human and murine TP53- MDM2 interactions, with nanomolar cellular IC50 values, blocking TP53 degradation[1] |
体内活性 | Tumors are allografted in large cohorts of mice to assess the pharmacologic effects of Siremadlin (NVP-HDM201). Sixteen out of 21 allograft models are sensitive to Siremadlin (NVP-HDM201) but ultimately relapse under treatment[1]. Siremadlin has recently entered Phase 1 clinical trials in cancer patients[2]. Siremadlin (NVP-HDM201) administered either daily at a low dose or once at a high dose revealed a differentiated engagement of the p53 molecular response. In contrast to the daily low dose treatment regimen, the single high dose Siremadlin (NVP-HDM201) regimen results in a rapid and dramatic induction of p53-dependent PUMA expression and apoptosis. This is consistent with the finding that a single high dose Siremadlin (NVP-HDM201) treatment, administered orally or intravenously, results in a robust and sustained tumor regression. Overall, both daily and once every 3 weeks dosing regimen shows comparable long term efficacy in preclinical studies. The ongoing clinical trial is currently designed to compare both dosing regimens with regard to efficacy and tolerability[3]. |
别名 | NVP-HDM 201 |
分子量 | 555.41 |
分子式 | C26H24Cl2N6O4 |
CAS No. | 1448867-41-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 56.75 mg/mL (102.18 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8005 mL | 9.0024 mL | 18.0047 mL | 45.0118 mL |
5 mM | 0.3601 mL | 1.8005 mL | 3.6009 mL | 9.0024 mL | |
10 mM | 0.18 mL | 0.9002 mL | 1.8005 mL | 4.5012 mL | |
20 mM | 0.09 mL | 0.4501 mL | 0.9002 mL | 2.2506 mL | |
50 mM | 0.036 mL | 0.18 mL | 0.3601 mL | 0.9002 mL | |
100 mM | 0.018 mL | 0.09 mL | 0.18 mL | 0.4501 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Siremadlin 1448867-41-1 Ubiquitination E1/E2/E3 Enzyme HDM 201 MDM-2/p53 NVP-HDM-201 E2 conjugating enzyme HDM201 Inhibitor HDM-201 NVP-HDM 201 Ubiquitin activating enzyme E3 ligating enzyme inhibit NVP-HDM201 E1 activating enzyme Ubiquitin ligase Ubiquitin conjugating enzyme inhibitor